Literature DB >> 15511465

Personal experience in surgical management of pulmonary pleomorphic carcinoma.

Federico Raveglia1, Maurizio Mezzetti, Tiziana Panigalli, Simone Furia, Luigi Giuliani, Serena Conforti, Stefano Meda.   

Abstract

BACKGROUND: Pleomorphic carcinoma is a rare epithelial malignant tumor. Pulmonary pleomorphic carcinoma was introduced by the 1999 World Health Organization classification as a new peculiar type of lung carcinoma showing concurrent malignant epithelial and sarcomatoid spindle cell elements. Few reports describe its clinical behavior. My colleagues and I report a series of patients surgically treated for pulmonary pleomorphic carcinoma to describe our experience with this malignant neoplasm.
METHODS: Twenty cases of pleomorphic pulmonary carcinoma were collected and studied clinicopathologically. All patients underwent surgical resection. The cases were as follows: 6 stage I, 12 stage II, and 2 stage IIIA. Histologic diagnosis was established by using light microscopic examination and immunohistochemistry. Survival rates were calculated with the Kaplan-Meier method.
RESULTS: We postoperatively diagnosed 20 cases of pleomorphic carcinoma: 14 cases were exclusively spindle and giant-cell carcinomas, 2 cases were spindle and giant-cell carcinoma combined with adenocarcinoma, 2 were combined with squamous cell carcinoma, and 2 were combined with large cell carcinoma. At last follow-up, 4 patients were still alive; they were postoperative T1 N0 and T2 N0. The remaining 16 patients died from early distant metastases. The median duration of disease-free survival was 5 months. The median duration of overall survival was 8 months.
CONCLUSIONS: The prognosis of patients with pleomorphic carcinoma was poor, despite surgery and adjuvant chemotherapy, because of early relapse of disease. Nodal involvement was a determinant prognostic variable, because advanced stages were related to worse prognosis. In case of preoperatively proven pulmonary pleomorphic carcinoma, surgery should be recommended to N0 patients.

Entities:  

Mesh:

Year:  2004        PMID: 15511465     DOI: 10.1016/j.athoracsur.2004.04.084

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  29 in total

1.  Combination of Pembrolizumab With Platinum-containing Chemotherapy for Pleomorphic Carcinoma of the Lung.

Authors:  Shinichiro Okauchi; Yuika Sasatani; Toshihiro Shiozawa; Hideyasu Yamada; Kunihiko Miyazaki; Norio Takayashiki; Hiroaki Satoh
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Local and systemic immunity predict survival in patients with pulmonary sarcomatoid carcinoma.

Authors:  Erin Schenk; Jennifer Boland; Aaron Mansfield; Marie Christine Aubry; Allan Dietz
Journal:  Med Oncol       Date:  2017-07-15       Impact factor: 3.064

3.  Clinicopathological factors influenced the prognosis of surgically resected pulmonary pleomorphic carcinoma.

Authors:  Katsuhiro Okuda; Risa Oda; Ayumi Suzuki; Tadashi Sakane; Osamu Kawano; Hiroshi Haneda; Satoru Moriyama; Ryoichi Nakanishi
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

4.  Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-β) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer.

Authors:  Anne S Tsao; Wei Wei; Elisabetta Kuhn; Loreto Spencer; Luisa M Solis; Milind Suraokar; J Jack Lee; Waun Ki Hong; Ignacio I Wistuba
Journal:  Clin Lung Cancer       Date:  2011-05-17       Impact factor: 4.785

5.  Vertebral metastases from giant cell carcinoma of lung: Images in cytopathology.

Authors:  Madhu Kumar; Madhu Mati Goel
Journal:  J Cytol       Date:  2015 Jan-Mar       Impact factor: 1.000

6.  Clinical outcomes with perioperative chemotherapy in sarcomatoid carcinomas of the lung.

Authors:  Jamie E Chaft; Camelia S Sima; Michelle S Ginsberg; James Huang; Mark G Kris; William D Travis; Christopher G Azzoli
Journal:  J Thorac Oncol       Date:  2012-09       Impact factor: 15.609

7.  Fine-needle aspiration cytology of pleomorphic carcinomas of the lung.

Authors:  Hee Seung Choi; Hyesil Seol; Il Yeong Heo; Chang Won Jung; Soo Youn Cho; Sunhoo Park; Jae Soo Koh; Seung-Sook Lee
Journal:  Korean J Pathol       Date:  2012-12-26

8.  The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma.

Authors:  Jung Yong Hong; Moon Ki Choi; Ji Eun Uhm; Min Jae Park; Jeeyun Lee; Yeon Hee Park; Jin Seok Ahn; Keunchil Park; Joung Ho Han; Myung Ju Ahn
Journal:  Med Oncol       Date:  2008-11-07       Impact factor: 3.064

9.  Pleomorphic carcinoma of the lung with high serum beta-human chorionic gonadotropin level and gynecomastia.

Authors:  Kerem Okutur; Baris Hasbal; Kubra Aydin; Mustafa Bozkurt; Esat Namal; Buge Oz; Kamil Kaynak; Gokhan Demir
Journal:  J Korean Med Sci       Date:  2010-11-24       Impact factor: 2.153

10.  Giant cell lung carcinoma in a man with acquired immunodeficiency syndrome.

Authors:  Takahide Kodama; Kunihiko Miyazaki; Hiroaki Satoh; Shigemi Hitomi; Morio Ohtsuka
Journal:  Med Oncol       Date:  2008-10-21       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.